Clinical trials: Other Drug Substance Abuse, active
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH-III (NCT02710331)
- Testing
- Active Dronabinol, Active Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH-II (NCT02710097)
- Testing
- Active inhaled cannabis, Active Oral Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH (NCT02404688)
- Testing
- Active delta-9-THC, Active Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH-I (NCT02709954)
- Testing
- Active inhaled delta-9-THC, Active Oral Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Polysubstance Abuse, Opioid Use
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient…
- Conditions
- Polysubstance Abuse, Opioid Use, Tobacco Use
- Trial name
- NCT06033599
- Testing
- MORE and MI and NRT, MORE and No MI and NRT, Support Group and MI and NRT
- Where
- 2 sites in United States
- Volunteers
- 420 people
- Sponsor
- Rutgers, The State University of New Jersey
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.